MetLife Investment Management’s Dianthus Therapeutics DNTH Stock Holding History

MetLife Investment Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.68M	Buy	27,536 +8,007	+41%	+$699K	0.01%	974
2026 Q1	$1.64M	Buy	19,529 +5,974	+44%	+$346K	0.01%	1164
2025 Q4	$559K	Buy	13,555 +3,942	+41%	+$153K	﹤0.01%	1742
2025 Q3	$378K	Sell	9,613 -4,480	-32%	-$114K	﹤0.01%	1945
2025 Q2	$263K	Hold	14,093	–	–	﹤0.01%	2034
2025 Q1	$256K	Sell	14,093 -279	-2%	-$6.15K	﹤0.01%	2069
2024 Q4	$313K	Buy	14,372 +433	+3%	+$11.1K	﹤0.01%	2047
2024 Q3	$382K	Buy	13,939 +7,854	+129%	+$219K	﹤0.01%	1932
2024 Q2	$157K	Buy	+6,085	New	+$146K	﹤0.01%	2387
2020 Q1	–	Sell	-641	Closed	-$155K	–	2261
2019 Q4	$155K	Hold	641	–	–	﹤0.01%	2116
2019 Q3	$105K	Hold	641	–	–	﹤0.01%	2292
2019 Q2	$151K	Buy	+641	New	+$158K	﹤0.01%	2186

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

MetLife Investment Management's DNTH Position: Q2 2026 in Review

MetLife Investment Management increased its Dianthus Therapeutics (DNTH) stake by 41% in Q2 2026, buying an estimated $699K and bringing the position to 27,536 shares worth $2.68M. The position accounts for 0.01% of the portfolio, ranked #974.

MetLife Investment Management first reported a position in DNTH in Q2 2019 and has held it in 12 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

MetLife Investment Management held 27,536 shares of Dianthus Therapeutics worth $2.68M as of Q2 2026.
MetLife Investment Management bought 8,007 Dianthus Therapeutics shares in Q2 2026, an estimated $699K.
Dianthus Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #974 holding.
MetLife Investment Management first reported a position in Dianthus Therapeutics in Q2 2019 and has held it in 12 quarters since.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.